UNSPSC 51323004: Levocarnitine acetyl

This classification denotes a nutritional supplement with the molecular formula C9H17NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DH1W9VH8Q, chemically known as l-(3-carboxy-2-hydroxypropyl)trimethylammonium hydroxide inner salt acetate, but more generally known as levocarnitine acetyl, which bears US NIH Compound Identifier 18230. European Medicines Agency schedules levocarnitine acetyl or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08466MIG.

Most nations, for tariff purposes, schedule levocarnitine acetyl under HS 29239000. SMILES: CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C.

UNSPSC 51323004 Levocarnitine acetyl is a Commodity code covering prescription and over-the-counter pharmaceutical products supplied to state and local health agencies, fire departments, and emergency medical services. State and local governments procure this product line as part of broader pharmaceutical supply contracts supporting emergency response systems, managed health plans, and institutional care programs. Recent solicitations show issuers ranging from municipal fire and rescue departments to state health agencies and multistate cooperative purchasing alliances, indicating demand across emergency response, pharmacy benefit administration, and direct-to-manufacturer distribution channels.

The Tampa Fire Rescue procurement (Bid No. 26P00188, due April 8, 2026) exemplifies municipal emergency medical services acquisition, where the City of Tampa's Purchasing Department solicited advanced life support medications including epinephrine, adenosine, diltiazem, and labetalol for use by Tampa Fire Rescue in Hillsborough County, Florida—a $40,000 contract with a one-year term and two optional renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a broader RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to work through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in late March 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. Activity is concentrated in the upper Midwest and Texas, with municipal and state health procurement offices as primary issuers; cooperative purchasing vehicles extend reach across multiple jurisdictions.